Publications, Pharmaceutical

Why it is time to think differently about Nasal delivery of Biologics

COVID-19 has reinvigorated interest in the advantages of nasal delivery for a pharmaceutical industry already embracing a shift towards biologics.

This article considers the challenges and potential benefits of combining the two. The nasal delivery of biologics offers considerable potential for both local and systemic action and for direct access to the brain and CNS to address currently unmet therapeutic need. The unique features of biologics are discussed with reference to the associated difficulties of nasal delivery and the benefits of partnership with experts such as Aptar Pharma is highlighted. Work on the development of vaccines and prophylactics for COVID-19 illustrates what is achievable.

Download Publication
Author(s): Gemma Budd Irene Rossi
4 Apr 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More About nasal drug delivery expertise

This Might Also Be of Interest

22 Apr 2021

Case Study – Pre-Clinical Respiratory Research with PADA

Case Studies, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
25 Mar 2021

Intranasal Immunization: Promises and Challenges

Webinars, Pharmaceutical, Sustainability, Innovation & Insights, Device Innovations, Market Insights, Product Solutions

Read More
19 Mar 2021

Otimização de processos no desenvolvimento de produtos inalatórios orais e nasais.

Webinars, Pharmaceutical, Product Solutions

Read More
27 Jan 2021

COVID 19: Drug Delivery Options to Succeed Sooner

Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Market Insights, Product Solutions

Read More
1 … 18 19 20 21 22 … 27

How Can We Help?

Back To Top